Share This Page
Drug Price Trends for NDC 72162-1113
✉ Email this page to a colleague
Average Pharmacy Cost for 72162-1113
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72162-1113
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 72162-1113
Introduction
NDC: 72162-1113 corresponds to Tucatinib, a targeted tyrosine kinase inhibitor approved by the FDA for treating HER2-positive breast cancer. Since its approval, tucatinib’s market dynamics, clinical position, and pricing have evolved amid competitive oncology therapeutics. This report provides a comprehensive analysis of the current market landscape and forecasts future pricing trajectories for tucatinib.
Market Overview
Therapeutic Indication and Unmet Needs
Tucatinib is primarily indicated for adult patients with unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, in combination with trastuzumab and capecitabine. HER2-positive breast cancers account for approximately 15-20% of breast cancers, representing a significant subset with historically aggressive progression and limited targeted treatment options before tucatinib's approval.
The drug addresses critical unmet needs by offering a targeted therapy that penetrates the blood-brain barrier, benefiting patients with brain metastases—an area where previous treatments had limited efficacy.
Market Penetration and Competitive Landscape
Since its FDA approval in April 2021, tucatinib has gained a notable position distinguished by its inclusion in combination regimens, notably the HER2CLIMB trial results demonstrating efficacy against brain metastases [1].
Key competitors include:
- Trastuzumab emtansine (T-DM1)
- Lapatinib
- Neratinib
- Tucatinib's unique benefit is its CNS activity, which has become a marketing leverage against competitors lacking this feature.
Initial uptake has been promising, especially within academic centers managing advanced HER2-positive disease.
Market Size and Demographics
The global breast cancer therapeutics market is projected to reach USD 21.5 billion by 2026, with targeted therapies constituting a burgeoning segment [2].
The specific niche for tucatinib comprises:
- Patients with metastatic HER2-positive breast cancer, including those with CNS metastases (~5,000–7,000 new cases annually in the U.S. alone).
- Patients resistant to or intolerant of prior HER2-targeted therapies.
This segment, although relatively small, is highly lucrative given the high unmet medical need.
Regulatory and Reimbursement Considerations
- The drug's accelerated approval based on phase II data indicates ongoing or forthcoming confirmatory trials.
- Reimbursement is increasingly secured through payer policies prioritizing CNS-active HER2 treatments, particularly after demonstrating survival benefits presented in clinical trials [3].
Pricing strategies are thus influenced by the therapeutic value and competitive positioning within the HER2 space.
Price Analysis and Projections
Current Pricing Landscape
As of 2023, the average wholesale price (AWP) of tucatinib ranges between $10,000 to $12,000 per month (depending on dosage and packaging), reflecting its premium position due to targeted indication and clinical benefit.
The pricing is notably higher compared to earlier-generation HER2 inhibitors, justified by its novel blood-brain barrier penetration and survival benefit data.
Historical Pricing Trends
- Since market entry, tucatinib’s price has stabilized amid rising competition and increasing adoption.
- Reimbursement dynamics and negotiated discounts heavily influence net prices.
Projected Price Trajectory
- Short-term (1–3 years): Prices are expected to stabilize, with potential minor reductions driven by competitive pressures and payer negotiations.
- Long-term (3–5 years): Prices might decline by 10-20%, as generic or biosimilar competitors could enter the market assuming patent expiry or if regulatory pathways permit biosimilar development.
Additionally, widespread adoption in combination therapy regimens, along with potential label expansions—such as earlier lines of therapy—could sustain premium pricing for longer periods.
Factors Influencing Future Prices
- Patent Life and Patent Challenges: Tucatinib’s patent exclusivity extends approximately until 2030, after which generics could emerge.
- Market Penetration & Volume: Higher adoption rates could enable volume-based discounts, balancing price erosion.
- Healthcare Policy: Payer pressure for cost containment and value-based pricing could lead to negotiated rebates.
- Clinical Data Advancement: Post-marketing studies confirming additional benefits could support sustained or increased pricing power.
Emerging Market Dynamics
- Biosimilar Competition: Although biosimilars are less common for small-molecule kinase inhibitors, generic manufacturing could contribute to future price declines.
- Orphan Drug Status and Market Exclusivity: The current orphan designation confers certain market protections, potentially bolstering pricing.
- Global Market Access: Premium pricing remains concentrated in high-income countries; emerging markets may experience delays or lower prices.
Regulatory and R&D Outlook
Future research, including phase III trials and real-world evidence, will influence market confidence and pricing. Positive survival and quality-of-life data could justify maintaining premium price points, especially if tucatinib becomes a standard component of HER2-positive breast cancer treatment.
Key Takeaways
- Tucatinib occupies a distinct niche targeting HER2-positive metastatic breast cancer with brain metastases, providing a unique competitive advantage.
- Current prices hover around $10,000–$12,000 per month, reflecting its clinical benefits and premium positioning.
- Short-term stability is expected, with modest reductions anticipated post-patent expiration or if biosimilar variants emerge.
- Long-term pricing will be shaped by clinical outcomes, regulatory developments, and competitive landscape evolution.
- The drug's market will remain lucrative within a high-income demographic, although volume growth and strategic negotiations are critical for sustained profitability.
FAQs
Q1. What factors justify the high price of tucatinib?
The premium price reflects its targeted mechanism, clinical efficacy—particularly CNS activity—and addressing unmet needs in HER2-positive metastatic breast cancer, especially in patients with brain metastases.
Q2. How does tucatinib's pricing compare to other HER2-targeted therapies?
Tucatinib’s monthly cost (~$10,000–$12,000) aligns with other targeted therapies like trastuzumab and T-DM1 but remains higher due to its novel CNS penetration feature and recent market entry.
Q3. What is the outlook for price reductions in the next five years?
Prices are expected to decline modestly (~10-20%) mainly due to patent expiration, increased generic competition, or negotiated payer rebates, assuming no further breakthrough data or label expansions that command premium pricing.
Q4. Will biosimilars impact tucatinib’s market and pricing?
While biosimilars are less common for small-molecule drugs, if biosimilar versions or alternative formulations emerge, they could exert downward pressure on prices.
Q5. How does clinical evidence influence pricing stability?
Strong clinical data supporting survival benefits and quality of life improvements reinforce justifications for higher prices, especially as tucatinib becomes a standard of care in its indications.
Sources
[1] Murthy et al., “HER2CLIMB trial results,” New England Journal of Medicine, 2021.
[2] Global Market Insights, “Oncology therapeutics market trends,” 2022.
[3] IQVIA Report, “HER2-positive breast cancer treatment landscape,” 2022.
More… ↓
